



«

»

---

**IV**

**21** :

• •

**29**      **2024**

**2024**



«

»

**IV**

**21 :**

• •

**29 2024**

**2024**

616.89  
56.14  
299

DOI: doi: 10.48612/cgma/arr1-3p77-92ru

299

IV

21 :

ISBN 978-5-907826-09-0.

« » ; IV  
 « 21 :  
 (29 2024 . ; .) ; . . . .  
 », 2024. – 80 .

« »  
 , 29 2024 . . . .  
 « » ,  
 « » ,  
 « » .

12.12.2024 6)

616.89  
56.14

ISBN 978-5-907826-09-0

© , 2024.  
 © . . , 2024.  
 © « » , 2024.

· ” · ·	.....	8
· ” · ·	.....	9
· ·	.....	11
· ” · ·	.....	13
· ” · ·	.....	14
· ·	.....	16
· ” · ” · ” · ”	.....	18
· ·	.....	19
· ·	.....	20
· ” · · «	.....	22
· ” · ” · ” · ·	.....	23
· ” · · ,	.....	25

· ” · ·	.....	26
· ” · ” · · -	.....	28
· ” · ”	.....	29
· ·	.....	32
· ” · · -	.....	34
· ·	.....	36
· ·	.....	37
· ·	.....	38
· ·	.....	39
· ” · ·	.....	41
· ” · ” · · : ( )	.....	43
· ” · · ,	.....	44
· · -	.....	46

60

..... 47

..... 49

..... 51

..... 53

..... 54

..... 56

..... 57

..... 60

..... 62

..... 63

..... 65

..... 67

..... 69

· · ·	:	.....	71
· · ·	,	.....	73
· · ·      · · ·	,	.....	75
· · ·      · · ·      · · ·	:	.....	76
· · ·      · · ·      · · ·	,	.....	77

... 1, ... 2

1  
2 6  
« »

E-mail: darja\_akimova@rambler.ru

COVID-19

SARS-CoV-2-  
[1-4].

41% , 2021- 89 588 , ,  
[1]. SARS-CoV-  
2 ,

[2-4].

89  
, 18-31 ( 21,8±1,7), COVID-19,  
SARS-CoV-2-

: 81% (n=72). , ( ,

( , ) 58,4% (n=52);  
) – 40,5% (n=36).  
23,6% (n=21),

, ) – 20,2% (n=18).

(n=31). 40,5% (n=36) - (STAI) – 34,8%  
48,3% (n=43)

) , – 41,6% (n=37). ( -  
: 22 ,

– 6 . , ,

, , COVID-19, ,

( ) . ,

COVID-19, [1-4].



## SARS-CoV-2-

1. Mental health of college students during the COVID-19 epidemic in China / W. Fu [et al.] // *Journal of Affective Disorders*. – 2021. – Vol. 1, No. 280 (Pt. A). – P. 7-10. doi: 10.1016/j.jad.2020.11.032.

2. The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2 / L. Bauer [et al.] // *Trends in Neurosciences*. – 2022. – Vol. 45, No. 5. – P. 358-368. doi: 10.1016/j.tins.2022.02.006

3. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis / J. Deng [et al.] // *Annals of the New York Academy of Sciences*. – 2021. – Vol. 1486, N . 1. – P. 90-111. doi: 10.1111/nyas.14506.

4. // . – 2022. – . 32, 2. – . 24-32.

. . 1, . . 2

1

2

*E-mail: vladaristova@gmail.com*

[1].

[2,3].

[4,5],

[6].

[7].

[8],

[9],

[9, 10, 11],

[12].

( - ).

».  
 ( 165 ): 31 , 36 « 35 75  
 98 ( - ).  
 SOMS-2 TAS-20  
 (  $r_s = 0,310$ ,  $p = 0,002$ ,  $n = 98$  )  
 (  $t = 3,702$ ,  $p = 0,353$ ,  $p =$   
 $0,000...1$ ,  $n = 98$  ) (  $r_s = 0,228$ ,  $p = 0,024$ ,  $n = 98$  ).  
 (  $t = 2,396$ ,  $p = 0,380$ ,  $p = 0,022$ ,  $n = 36$  ),  
 (  $t = 2,417$ ,  $p = 0,409$ ,  $p = 0,022$ ,  $n = 31$  ),

1. Van den Bergh O., Zacharioudakis N., Petersen S. Interoception, categorization, and symptom perception. In: M. Tsakiris, H.D. Preester (Eds.) *The interoceptive mind: From homeostasis to awareness*. – New York: Oxford University Press, 2018. – P. 212-226.

2. Longarzo M., D'Olimpio F., Chiavazzo A., et al. The relationships between interoception and alexithymic trait. *The Self-Awareness Questionnaire in healthy subjects // Frontiers in Psychology*. – 2015. – Vol. 6. – N 1149. – P. 1-8.

3 Terasawa Y., Oba K., Motomura Y., et al. Paradoxical somatic information processing for interoception and anxiety in alexithymia // *European Journal of Neuroscience*. – 2021. – Vol. 54. – N 11. – P. 8052-8068.

4. Ernst J., Böker H., Hättenschwiler J., et al. The association of interoceptive awareness and alexithymia with neurotransmitter concentrations in insula and anterior cingulate // *Social Cognitive and Affective Neuroscience*. – 2014. – Vol. 9. – N 6. – P. 857-863.

5. Betka S., Pfeifer G., Garfinkel S., et al. How do self-assessment of alexithymia and sensitivity to bodily sensations relate to alcohol consumption? // *Alcoholism: Clinical and Experimental Research*. – 2018. – Vol. 42. – N 1. – P. 81-88.
6. Longarzo M., D'Olimpio F., Chiavazzo A., et al. The relationships between interoception and alexithymic trait. The Self-Awareness Questionnaire in healthy subjects // *Frontiers in Psychology*. – 2015. – Vol. 6. – N 1149. – P. 1-8.
7. Zamariola G., Vlemincx E., Corneille O., et al. Relationship between interoceptive accuracy, interoceptive sensibility, and alexithymia // *Personality and Individual Differences*. – 2018. – Vol. 125. – P. 14-20.
8. Kooiman C.G., Bolk J.H., Brand R., et al. Is alexithymia a risk factor for unexplained physical symptoms in general medical outpatients? // *Psychosomatic Medicine*. – 2000. – Vol. 62. – N 6. – P. 768-778.
9. Porcelli P., Taylor G.J. Alexithymia and physical illness: A psychosomatic approach. In: O. Luminet, R.M. Bagby, G.J. Taylor (Eds.) *Alexithymia: Advances in research, theory, and clinical practice*. – New York: Cambridge University Press, 2018. – P. 105-126.
10. Kano M., Grabe H.J., Terock J. Genetic Factors and Endocrine and Immune System Functioning Associated with Alexithymia. In: O. Luminet, et al, 2018. – P. 267-290.
11. Panayiotou G., Panteli M., Vlemincx E. Processing emotions in alexithymia: A systematic review of physiological markers. In: O. Luminet, et al, 2018. – P. 291-320.
12. Leonidou C., Panayiotou G. How do illness-anxious individuals process health-threatening information? A systematic review of evidence for the cognitive-behavioral model // *Journal of Psychosomatic Research*. – 2018. – Vol. 111. – P. 100-115.

:

. .

*E-mail: vladaristova@gmail.com*

( ) ,

( )

( , ).

, , - , - ,

.

.

.

.

,

.

,

,

,

· ,

( , ,

,

, )

,

,

,

.

-

,

,

,

.

.

,

,

.

-

-

.

(

)

,

,

,

,

-

.

,

,

.

,

.

,

,

(

,

,

).

,

,

,

.

.

,

,

,

.

, , , .  
- ,  
, ,  
.

1. . „ . „ // . -  
2023. - . 69. - 6. - . 121-131.
2. . „ . „ . . . //  
. - 2023. - . 90. - 4. - . 45-48.
3. . . c :  
// . - 2015. - . 155. - 11. - . 40-45.

-

. . 1, . . 2, 3

1 . . . ” 15 - „  
1 . . »

2 « . . . »

3 « - . . . »  
- , ,  
*ppsy@list.ru*

[1].

« 1 . . . »  
15» « «

»  
 1993 2020  
 3 10 ( 2021  
 1109  
 814

2022  
 ),  
 (

/ ;  
 3,6 ±1,3 , 8,5% 5,7±1,4 / ; 56,3%  
 ; /  
 ( -17,8%);

;  
 / ;  
 ; / / ;  
 ; /

.. // : . - 2018. - . 28. - 3. . 74- 81.

: -  
 . . 1, . . 2

1  
 2  
 , . . . .  
 -

« . . . »

E-mail:<sup>1</sup>akhmedova.ayna@yandex.ru; <sup>2</sup>gorobetsln@mail.ru

. - , [1].  
45 68%,  
[2]. ,  
(« », , ) [3].  
, -  
, [3, 4]. -

, [3].  
,  
.

. -  
,  
,  
90  
- 41 (1 ), - 49 (2  
) . - 52,57±0,85 . : - ,  
,  
,  
(87,8%) . 1 (63,4%)  
, 2 - (59,2%).  
, ( , ,  
, . .) , ( p<0,05); ( , ,

,  
, HADS HAM-A  
HADS HAM-D. ISI PSQI  
PSQI  
:  
,  
« », , ,  
, ( , , , , ,  
) - , ,

( =0,3 =3,9 ( =2,3, p<0,001) , p<0,001). (r=0,44 r=0,36 , p<0,05). ( =1,6, p<0,001) ( =3,0 p<0,001), ( =1,8 =0,3, , p<0,001).

1. Willi J. Assessment of perimenopausal depression: A review / J.Willi, U. Ehlert // J. Affect. Disord. - 2019. - Vol. 249. - P. 216–222.

2. // ( ). - 2016. - . 18, 6. - . 30–36.

3. Kornstein S.G. The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women / S.G.Kornstein, E.A.Young, A.T. Harvey et al. // Menopause. - 2010. - Vol. 17. - P. 828-839.

4. // . - 2022. – 32, 4. – 25–30.

« »  
E-mail: y.v.barmenkov@gmail.com

[1].

( ) [2].

[3].



[4].

[5, 6]

( )

( 14-18 , F21.x, F84.5, F9x, )

( = 15,7, SD = 1,55), ( = 15,5, SD = 1,29)

17 ( F21.x). - 4 ( = 17, SD = 1,41)

(F84.5, F84.8). 7

(2 ,5 , = 14,75, SD = 0,96)

(F9x).

(PAQ),

( ),

(AIDA),

JASP (Version 0.18.3):

U

r

(p < 0,01)

).

1. Mishara A.L., Lysaker P.H., Schwartz M.A. Self-disturbances in schizophrenia: history, phenomenology, and relevant findings from research on metacognition. // *Schizophrenia bulletin*. – 2014. – Vol. 40. – N. 1. – P. 5–12.

2. Montemagni C., Sgro R., Brasso C., Rocca P. Metacognition, social cognition, and social functioning in schizophrenia: Current evidence. // *Journal of Psychopathology*. – 2024. – Vol. 30. – N. 1. – P. 53–61.

3. . . . //

. . . . – 2015. – . 115. – 11-2. – . 20-25.

4. Branje S., de Moor E. L., Spitzer J., Becht A.I. Dynamics of Identity Development in Adolescence: A Decade in Review. // *Journal of research on adolescence: the official journal of the Society for Research on Adolescence*. – 2021. – Vol. 31. – N. 4. – P. 908–927.

5. // . . . . – 2022. – . 2. – 1. – . 5-33.

6. . . . // . . . . – 2016. – . 9. –

46. – . 1. URL: <http://psystudy.ru> ( : 23.10.2024).

<sup>1</sup> . . . .<sup>1</sup> . . . .<sup>1,2</sup> . . . .<sup>1</sup> . . . .<sup>1</sup> . . . .

<sup>2</sup> « <sup>1</sup> 02035, . . . . , » , .

*E-mail: beloivan\_nat@mail.ru*

1/3

7,5

27%  
[1].

[2, 3].

(HADS),

0 7

, 8-10

11

19

27

(57%

47  
46±0,25

28

).

7 (26%) 14 (52%)  
 (11%) .3 (11%) HADS  
 10 (50%) 10 (50%)  
 :

1. Hajak G. Insomnia in primary care //Sleep. – 2000. – 23 (Suppl. 3). – P. 54–63.
2. Grewal R, Doghramji K. Epidemiology of insomnia. In: Attarrian HP, Schuman C, editors. Clinical Handbook of insomnia. Springer Science+Business Media, LLC; 2010. P. 13-22.
3. Morin CM, Jarrin DC. Epidemiology of insomnia. Prevalence Course, Risk Factors, and Public Health Burden. Sleep Med Clin. 2013; (8):281-97.

« »

*beresneva.annaf@gmail.com*

[1].

[2].

16-25 ( F31.3-4, F34.0

19.1 ± 3.3) -10.

23

« »,

[3].

8-

(HDRS-17)

SCL-90.

«STATISTICA, v.12»

( ).

(p<0,05)

HDRS-17

(r=-0,543), HDRS-17 (r=-0,448), (r=-0,563)  
 (r=-0,492 r=-0,495).  
 SCL-90 (p<0,01) : (r=-0,555); (r=-0,560), (r=-0,729); (r=-0,544)  
 (r=-0,612), (r=-0,597). (p<0,05) (r=-0,426)  
 SCL-90 (p<0,05) r=-0,454),  
 : -1 (8-9 )  
 ; -3 (11-13 ) [4].  
 ( .3 HDRS-17):  
 SCL-90,

1. Rotter J. B. Generalized expectancies for internal versus external control of reinforcement. Psychological Monographs: General and Applied. 1966. – V.80. – N.1. – P.1-28.
2. . . . / . . . // . . . : . . . , 1988. .43-89.
3. . . . : . . . . – ; - . . . , 2001. 224 .
4. Mathersul D., Williams L.M, Hopkinson P.J, Kemp A.H. Investigating models of affect: relationships among EEG alpha asymmetry, depression and anxiety. Emotion. 2008. – V.8. – N4. – P. 560-572.

E-mail: anastasiavolodarskaya7@gmail.com

80% ) [1,2].  
( ),

[3].

87  
( , n = 40),  
- 23,7±2,3 , ( , n = 47).  
- 23,2±2,3 .

«PEBL Change Detection», «  
«PEBL Dexterity», « - » «  
« -Next».

t-

«PEBL Change Detection»  
- 15,53±4,14, - 19±0,82,  
- 2,76±1,72, - 4,43±0,79,

14085,24±7513,53 , - 7847,46±3607,79 , - 19284,08±9991,11 , -  
11074,43±6194,03 , - 42860,82±17965,17 , - 27220,8±21497,86 ,  
(p<0,05).

- 21458,16±10331,73 , - 9914,89±3954,95 (p<0,01).  
« ,»

- 98,1 ± 21,96, - 121,43 ± 4,2  
- 6,63 ± 2,03,  
(p<0,05),  
- 8,29 ± 1,11 (p<0,01).

«PEBL Dexterity» ,  
- 2287,45±797,2 , - 1643,72±227,36  
(p<0,01),  
- 138,79±44,2, - 104,3±13,28 (p<0,01).

« - » ,  
- 2,88 ± 7,13%, - 0,18 ± 0,3%  
(p<0,05).

« - »  
- 153,2±14,28, - 167,71±11,1,  
- 126,09±5,04,  
- 144,71±20,23.  
- 29,75±7,77%, - 18,11±9,57%,  
- 767,18±554,83 , - 1470,86±723,98 (p<0,01).

- 1. Vosviewer (2005-2021 .) / . . . , . . .  
 // - . - 2023. - 3. - . 106-121.
- 2. / . . . , . . . [ . ] //  
 . - 2022. - 3. - . 14-24.
- 3. , . . . -  
 // / . . . , . . .  
 . - 2020. - . 11, ' 1. -  
 . 22-32.

« »

. . .<sup>1</sup>, . . .<sup>2</sup>

<sup>1</sup> , <sup>2</sup>

« - , . . . »

E-mail: vanchandang@gmail.com

32

( ) 36 ( , ).

« » [1], «PsychoPy 3».

(50%) (12%) (%) , (88%),

( ), / ( ).

t-

p<0,05.

$(56,39 \pm 10,02)$ ,  $(81,78 \pm 7,09)$   $(85,89 \pm 6,41)$   $(70,39 \pm 9,51)$   
 $(18,37 \pm 1,97)$ ,  $(26,78 \pm 14,51)$ ,  $(88\%)$   
 $(6,05 \pm 1,08)$ ,  $(3,86 \pm 4,3)$   
 $(6,41 \pm 0,94)$   $(17,20 \pm 2,76)$

1. Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia / M.T. Treadway, N.A. Bossaller, R.C. Shelton [et al.] // Journal of abnormal psychology. – 2012. – Vol.121(3). – P.553-558. doi: 10.1037/a0028813.

$\cdot \cdot \cdot^{1,2}$ ,  $\cdot \cdot \cdot^{1,2}$ ,  $\cdot \cdot \cdot^2$ ,  $\cdot \cdot \cdot^2$   
1

2 « »  
E-mail: kirilochev@gmail.com

[1].

[2].

34

60 92

76,47 ( $\pm 9,69$ )

: «F02.  
 » (41,18%), «F01. » (20,6%), «F06.  
 » (17,6%), «F20. » (11,8%), «F00.  
 » (5,9%), «F03. » (2,9%).  
 – 9, – 4,41 ( $\pm 1,92$ ), – 1, 14  
 (41,18%). [3],

2023 «Falls at the interface between geriatric and psychiatric patients: a critical review from a psychopharmacological perspective» [2].

StatPlus:mac, 7.3.1.0. AnalystSoft Inc.,  
 67% 1 (14,7%)  
 « »  
 « »  
 2,9% , 23,6% 73,5%.  
 (p>0,05).

1. Seppala L.J. Fall-risk increasing drugs: a systematic review and meta-analysis: II. Psychotropics / L.J. Seppala, A.M.A.T. Wermelink, M. de Vries [et al.] // J Am Med Dir Assoc – 2018. – Vol. 19,4. P. 371.e11-371.e17.

2. Wedmann F.M. Falls at the interface between geriatric and psychiatric patients: a critical review from a psychopharmacological perspective / F.M. Wedmann, A. Conca, P. Di Gregorio [et al.] // Riv Psichiatr. – 2023. – Vol. 58, 5. P. 195-204.

3. Morse J.M. Development of a Scale to Identify the Fall-Prone Patient. / J.M. Morse, R.M. Morse, S.J. Tylko // Canadian Journal on Aging. – 1989. – Vol. 8, 4. P. 366-377.



1  
2  
« »

*E-mail:alexkozachuk@yandex.ru*

« » [1,2,3,4],  
6-9% 2001-2005 . 28%  
2018 . [5].

[6].

(F20)  
(F25)  
(F20.81),  
-10  
(F23) [7].

“ - ” ( ).  
27  
( ) 2023 2024 .

27  
- 36  
- 5,73  
- 2,07

» 22 «  
F43.0.» « . F43.2.»

5

. F23.» 3

1. Armed Forces Health Surveillance Center (AFHSC). Medical evacuations from Operation Iraqi Freedom/Operation New Dawn, active and reserve components, U.S. Armed Forces, 2003-2011. MSMR. 2012 Feb;19(2):18-21. PMID: 22372753.

2. Belmont PJ Jr, Goodman GP, Waterman B, DeZee K, Burks R, Owens BD. Disease and nonbattle injuries sustained by a U.S. Army Brigade Combat Team during Operation Iraqi Freedom. Mil Med. 2010 Jul;175(7):469-76. doi: 10.7205/milmed-d-10-00041. PMID: 20684449.

3. Hauret KG, Pacha L, Taylor BJ, Jones BH. Surveillance of Disease and Nonbattle Injuries During US Army Operations in Afghanistan and Iraq. US Army Med Dep J. 2016 Apr-Sep;(2-16):15-23. PMID: 27215861

4. Armed Forces Health Surveillance Center (AFHSC). Causes of medical evacuations from Operations Iraqi Freedom (OIF), New Dawn (OND) and Enduring Freedom (OEF), active and reserve components, U.S. Armed Forces, October 2001-September 2010. MSMR. 2011 Feb;18(2):2-7. PMID: 21793603

5. Armed Forces Health Surveillance Branch : Medical evacuations out of the U.S. Central Command, active and reserve components, U.S. Armed Forces, 2018 // Medical Surveillance Monthly Report. – 2019. - Vol. 26. – N. 5. – P. 28-33.

6. Migliore L. et al. Considerations for acute and emergent deployed mental health patient management and theater transports: a scoping review // Military medicine. – 2021. – Vol. 186. – N. 9-10. – P. e932-e942.

7. Hann MC, Caporaso E, Loeffler G, Cuellar A, Herrington L, Marrone L, Yoon J. Early interventions in a US military FIRST episode psychosis program //Early Intervention in Psychiatry. – 2018. – Vol. 12. – N. 6. – P. 1243-1249.

«

»

*E-mail: dmitrikolesnikov99@gmail.com, kvrybakova@yandex.ru*

[1].  
 [2].  
 63  
 (53 (84,13%) – ),  
 , 10 (15.87%) –  
 «  
 »  
 (2013 ). 14 (26.42%) 39  
 (73.58%), 38,6±7,2  
 33,5±4,7  
 -10.  
 : 1- – (n=51), 2- – (n=12).  
 (MoCa),  
 (MMSE)  
 (FAB). Statistica V. 12.5  
 (p 0,05).  
 MoCa ( 9 , p<0,05).  
 MMSE FAB,  
 MoCa.  
 MoCa

1. Kaneko K. Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning. / Kaneko K. // Yonago Acta Medica. – 2018. – Vol. 61 – N. 2. – P. 091–102.

2.

/ . . . // . – 2013. – . 23. – . 19-23.

1  
2  
3  
« »

E-mail: mariakochergina.s@gmail.com

( )  
40  
3,5% [1].  
[2].  
73,6%  
[3]. , 88% [4].  
[5].  
[6].  
HADS ( ), MFI-20  
( ), PANSS ( ), SRRS ( ).

62,5% (n=10) 16 .

1. ( ) (n=5) (F34.1 – 20%; F62.8 – 80%);

2. ( ) (n=5) (F20.3 – 40%; F20.4 – 40%; F25.2 – 20%).

7±2

(HADS),

(MFI-20);

3±1,5

(PANSS), 100%

1. Li M. et al. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis //Climacteric. – 2023. – . 26. – . 2. – . 95-102.
2. 2035 .// : [ ] . – URL: <https://rosstat.gov.ru/folder/12781> ( 30.09.2024).
3. Schmidt P. J. et al. Depression in women with spontaneous 46, XX primary ovarian insufficiency //The Journal of Clinical Endocrinology & Metabolism. – 2011. – . 96. – . 2. – . E278-E287.
4. Sun J. et al. Chronic and cumulative adverse life events in women with primary ovarian insufficiency: an exploratory qualitative study //Frontiers in Endocrinology. – 2022. – . 13. – . 856044.
5. Iwasa T. et al. The roles of kisspeptin and gonadotropin inhibitory hormone in stress-induced reproductive disorders //Endocrine Journal. – 2018. – T. 65. – . 2. – C. 133-140.
6. Xu Y. P. et al. Psychological stressors involved in the pathogenesis of premature ovarian insufficiency and potential intervention measures //Gynecological Endocrinology. – 2024. – . 40. – . 1. – . 2360085.

E-mail: kuleshov-aa-ncpz@yandex.ru

..

E-mail: krylovaes@gmail.com

( )

[1].

17.9% 46.2%; [2,3].

[4].

26,3%

[5]

[6].

... ) : ( ... -  
: ( ... )  
1. (16-25 )  
2.

(F21.8). (F31.X-F34.X), (F60.X-F61.X),  
3.  
4.

1.  
2.  
63  
2020-2024  
1.  
(15 ) -

2. (23 ) –  
 (16 (70%),  
 [7]  
 3.  
 (25 )  
 (18 (72%)

### 1.

	11 (73%)	2 (9%)	3 (12%)
	1 (7%)	16 (70%)	4 (16%)
	3 (20%)	5 (22%)	18 (72%)
2	18,41634615	13,70986622	9,740576923
P	0,001023032	0,008281002	0,045031876

1. Rizzo A. Wanna bet? Investigating the factors related to adolescent and young adult gambling / A. Rizzo, V.L. La Rosa, E. Commodari, D. Alparone, P. Crescenzo, M. Yildirim, F. Chirico //European Journal of Investigation in Health, Psychology and Education. – 2023. – . 13. – . 10. – . 2202-2213.

2. Moñino-García M. The adolescent problem gambling prevalence associated with leisure-time activities and risky behaviors in Southern Spain / M. Monino- García, M. Ballesta,

J.M. Huerta, J.F. Correa-Rodríguez, N. Cabrera-Castro, N. Llorens, M.D. Chirlaque-López //International journal of mental health and addiction. – 2024. – . 22. – . 3. – . 1662-1676.

3. Tran L.T. The prevalence of gambling and problematic gambling: a systematic review and meta-analysis / L.T. Tran, H. Wardle, S. Colledge-Frisby, S. Taylor, M. Lynch, J.Rehm, R. Volberg, V. Marionneau, S. Saxena, C. Bunn, M. Farrell, L. Degenhardt //The Lancet Public Health. – 2024. – .9. – . 8. – . 594-613.

4. Vijayakumar L. Online gambling and suicide: Gambling with lives / L. Vijayakumar, V. Vijayakumar // Indian journal of psychiatry. – 2023. – . 65. – . 1. – . 3-4.

5. Huțul T. D. The level of gambling prediction using depression and anxiety in the Romanian population / T.D. Hutul, A. Karner-Huțuleac //Journal of Gambling Studies. – 2022. – . 38. – . 2. – . 653-662.

6. Nurmagandi B. The correlation between depression with online game addiction among adolescents: Systematic review/B. Nurmagandi. D. Suratmini //Journal of Psychiatric Nursing/Psikiyatri Hemsireleri Dernegi. – 2024. – . 15. – . 1.– C. 93-102.

7. Zhao Y. Network analysis of internet addiction and depression among Chinese college students during the COVID-19 pandemic: a longitudinal study / Y. Zhao. D. Qu, S. Chen, X. Chi //Computers in Human Behavior. – 2023. – . 138. – . 107424.

• •

« »

*E-mail: manushina1996@yandex.ru*

( )

[1,2].

[3].

[4],

[5].

80

50%

, 50%

18-40

- Personal and Social Performance scale (PSP),  
- Global Assessment Scale (GAF).



## Positive and Negative Syndrome Scale (PANSS).

R (4.2.2)

[6, 7],

PSP

$\pm 3,79$  (p=0,003),  
 (p=0,002)  
 $80,7 \pm 5,16$

$3,12 \pm 6,76$   
 $4,52 \pm 3,16$   
 $76,1 \pm 9,79$

$60,8 \pm 6,79$

$57,21 \pm 6,71$

$1,89 \pm 2,64$   
 $2,15 \pm 1,76$   
 $2,87 \pm 6,46$

PSP  
 (p=0,002).  
 (p <0,001).

$72,94 \pm 9,17$   
 $75, 88 \pm 10,83$

$65,81 \pm 11,25$   
 $70,78 \pm 8,44$

(p <0,001) (GAF),  
 (p <0,001) (PSP).

[8],

[9, 10].

$15, 91 \pm 4,50$   
 (PANSS)

$8,21 \pm 2,42$

$11,65 \pm 4,43$

$17, 77 \pm 3,64$

$17,05 \pm 3,61$

$10,12 \pm 3,45$

$15, 21 \pm 3, 75$

$13,25 \pm 2,47$

(p <0,001)  
 (p <0,001) (PANSS)  
 (p <0,001) (PANSS)  
 (p <0,001) (PANSS)

1. . . . .

//

. 2014.- .3.- .67-72

2. Prakash J, Chatterjee K, Srivastava K, Chauhan VS. First-episode psychosis: How long does it last? A review of evolution and trajectory // Ind Psychiatry J. -2021.-V.7.-P. 198-206. doi: 10.4103/ipj.ipj\_38\_21.

3. Thibaudeau E., Cellard C., Functional Impairments and Theory of Mind Deficits in Schizophrenia: A Meta-analysis of the Associations.//Schizophrenia Bulletin. – 2021. –V. 47. - 3.-P.695–711. doi.org/10.1093/schbul/sbaa182

4. Riecher-Rössler, A. Sex and gender differences in mental disorders // The Lancet Psychiatry. -2017.- V.1. –P.8–9. doi.org/10.1016/S2215-0366 (16)30348-0

5. Giordano GM, Bucci P, Mucci A, et al. Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia // A Mini Review. *Frontiers in psychiatry*. – 2021.-V. 12. Article.789179. doi.org/10.3389/fpsy.2021.789179

6. . . . // . 2018. – .5.- .43-51.

7. Wojciak P, Domowicz K, Andrzejewska M, Rybakowski JK Negative symptoms in schizophrenia, assessed by the brief negative symptom scale, self-evaluation of negative symptom scale, and social cognition: a gender effect // *International journal of psychiatry in clinical practice*. -2021-. V.25.- P. 252–257. doi.org/10.1080/13651501.2020.18102

8. Estancial F., de Azevedo R.C., Goldbaum M. et al. Psycho-tropic use patterns: Are there differences between men and women? // *PLOS One*. -2018.-V.13.-P. 11-14. doi.org/10.1371/journal.pone.0207921

9. Riecher-Rössler, A. Sex and gender differences in mental disorders.// *The Lancet Psychiatry*. -2017-. V.4.-P.8–9. doi.org/10.1016/S2215-0366 (16)30348-0

10. Dama M., Veru F., Schmitz N. et al. Sex differences in clinical and functional outcomes among patients treated in an early intervention service for psychotic disorders: An observational study // *Canadian journal of psychiatry*. -2019.-V. 64.-P. 708–717. doi.org/10.1177/0706743719854069

-

. .

« »

,

,

*E-mail: alena.melnik.94@inbox.ru*

. .

,

,

,

« »

,

,

,

,

,

.

-

.

-

,

,

[1].

- (A )



. .

« »

*E-mail: voviand.vm@gmail.ru*

[1].

*de novo* SLC6A1,  
( ) [2].

15

F25

F20

[3].

( )

qPCR  
SOX2, TRA-1-60, TRA-1-81, SSEA-4,

OCT4,

SLC6A1

STR-

the Human Pluripotent Stem Cell Registry

MHRCCGi001-A ( ), MHRCCGi005-A ( ) MHRCCGi004-A ( ).  
( )

Dual-SMAD

[4].

- BDNF, GDNF cAMP.

-III-tubulin, ASIC1, GAD67, NSE, Nkx2.1, vGlut2, GABA.

SLC6A1.

*in vitro*,

1. Singh T., Poterba T., Curtis D., et al. Rare coding variants in ten genes confer substantial risk for schizophrenia // *Nature*. 2022, 604(7906), 509-516. doi: 10.1038/s41586-022-04556-w.

2. Rees E., Han J., Morgan J., et al. *De novo* mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia // *Nat Neurosci*. 2020, 23(2), 179-184. doi: 10.1038/s41593-019-0565-2.

3. Kondratyev N.V., Alfimova M.V., Kaleda V.G., et al. Assessing the impact of the *de novo* SLC6A1 mutation in schizophrenia through a comprehensive case study // *Psychiatry Res.* 2023, 327(115399). doi:10.1016/j.psychres.2023.115399

4. Imaizumi K., Okano H. Modeling neurodevelopment in a dish with pluripotent stem cells // *Dev Growth Differ.* 2021, 63(1): 18-25. doi: 10.1111/dgd.12699

..

« - ( - . . . » )

E-mail: rosenzweigjoe@mail.ru

[1],

68 , 47 115 - ( ) (23,2±2,6 vs 23,7±2,3).

« » [2]. (HF), (HFnorm), (TP), R-R ( ), R-R ( ), ( ), ( ) , t- p<0,05.

HF ( - 450,01±742,98 vs 1357,104±1177,8 , - 325,41±369,16 vs 1351,9±1143,23; - 577,93±786,62 vs 1241,94±1017,49), HFnorm ( - 29,39±12,47 vs 38,24±11,9, - 29,30±12,69 vs 36,55±10,71, - 31,35±14,04 vs 37,09±10,87), TP ( - 1651,27±1946,47 vs 4820,17±3009,76, - 1405,7±1666,47 vs 5041,61±2905,5, - 1852,3±1839,99 vs 4624,96±2870,16), ( - 39,6±22,39 vs 69,03±19,62, - 35,65±20,95 vs 73,46±18,61, - 46,7±28,22 vs 67,72±18,15) ( - 59,2±12,73 vs 37,1±7,39, - 60,71±13,71 vs 36,55±6,92, - 59,31±13,29 vs 37,5±7,29).

HF (-118,18±639,06 vs 236,65±609,93), (-4,83±14,53 vs 6,43±9,93), (1,2,3,4) (1,2,3,4) (1,2,3,4) (-3,47±10,31 vs

8,46±11,1)

TP  
(2482,7±1572,24 vs 1171,57±1332,82 17,08±7,62 vs 11,89±8,26, TP (2371,86±1572,24 vs 1382,93±1516,18)

(4,89±2,37 vs 9,22±3,75) / (5,21±2,3 vs 8,86±3,83)

( HF) TP )  
( . . . ) ,  
« » [3]

1. „ „ „ / . . . , . . . // . - 2021. - . 31, 2. - . 51-57.
2. [ . . . ] // - . - 2023. - . 344, 7. - . 4-15. - DOI 10.52424/00269050\_2023\_344\_7\_4. - EDN FNCQIP.
3. Laborde S., Mosley E., Mertgen A. Vagal Tank Theory: The Three Rs of Cardiac Vagal Control Functioning – Resting, Reactivity, and Recovery // Front. Neurosci. – 2018. – Vol. 12. – P. 458. doi: 10.3389/fnins.2018.00458.

E-mail: moritzar@mail.ru

( )

[1]. 2 :  
 [2].  
 [3].  
 [4].  
 40  
 15,8 (7,4)  
 37,5 (9,6)  
 PANSS 73,5 (11,6). PANSS :  
 BNSS;  
 CDSS, -  
 SAS;  
 PSP.  
 (F=17.1, p<0,001, R<sup>2</sup>=0,64,  
 d=1,64)  
 64%  
 ( =-0,6, p<0,001), ( =-0,3, p=0,006),  
 ( =0,3, p=0,009).

1. Long M. A systematic review of social functioning outcome measures in schizophrenia with a focus on suitability for intervention research / M. Long, J.L. Stansfeld, N. Davies, N.E. Crellin, J. Moncrieff // *Schizophrenia Research*. – 2022. – Vol. 241. – P. 275–91.

2. Galderisi S. Negative symptoms of schizophrenia: new developments and unanswered research questions / S. Galderisi, A. Mucci, R.W. Buchanan, C. Arango // *Lancet Psychiatry*. – 2018. – Vol. 5. – N. 8. – P. 664–677.

3. Mosolov S.N. Primary and Secondary Negative Symptoms in Schizophrenia / S.N. Mosolov, P.A. Yaltonskaya // *Frontiers in Psychiatry*. – 2022. – Vol. 12. – P. 766692.

4. Handest R. A Systematic Review and Meta-Analysis of the Association Between Psychopathology and Social Functioning in Schizophrenia / R. Handest, I. Molstrom, M.G. Henriksen, C. Hjorthøj, J. Nordgaard // *Schizophrenia Bulletin*. – 2023. – Vol. 49. – N. 6. – P. 1470–1485.

• •

• • •

e-mail: [niknaum2003@yandex.ru](mailto:niknaum2003@yandex.ru)

[1],

« » . . [2]

[2] ( , « ,

?»),

0% 100%, 10

61 , +-20,2 , 62,9%

(DES) [2],

(DES).

0,931,

?»).

(DES).

0,552,

-0,0972327.



1. . . . . :  
 . - . : - , 2013 – 496 .
2. . . . . — :  
 , 2001. — 272 .

. . , . .  
 « . »  
 ,  
*evgeniyanechushkina@gmail.com*

( ) - [1].  
 XX

[2].

[3].

— ; 29,1±7,9 ) 25 (15 – , 10  
 «

» (F21.8) -10,  
 .  
 .  
 ( ) : ,  
 , . (6 .)  
 « » [4].  
 ,  
 ( 1,6±1,1 )  
 .  
 (13 .)  
 ( ) [5].  
 ( 2,3± ,6 )  
 ( , , ) [6].  
 2/3 (9 .)  
 - ,  
 ( )  
 .  
 (6 .)  
 ( - )  
 , )  
 :  
 ( 8,7±4,7 ),  
 ( , )  
 ( )  
 ,  
 ,  
 ,  
 ,  
 ( , )

1. Fonseca-Pedrero E. et al. Schizotypal traits and depressive symptoms in nonclinical adolescents //Comprehensive psychiatry. – 2011. – . 52. – . 3. – . 293-300.

2. . . . . ( )

// .... . – 1987. – . 8.

3. Lewandowski K. E. et al. Anxiety and depression symptoms in psychometrically identified schizotypy //Schizophrenia research. – 2006. – . 83. – . 2-3. – . 225-235.

4. Shimoda M. On manic-depressive illness //Yonago Igakushi. – 1950. – . 2. – . 1-2.

5. Kemp K. C. et al. Association of positive, negative, and disorganized schizotypy dimensions with affective symptoms and experiences //Psychiatry Research. – 2018. – . 270. – . 1143-1149.

6. . . . . ( ) // . – 1997. – . 28-54.

: ( )

. . 1, . . 2, . . 3

1

2

3

dm.nozdrachev@yandex.ru

» ( . 124020800064-9).

( ) .

[1,2,3].

[4].

45/10 23.09.2024 ).

M.I.N.I.,

( MADRS, HARS, YMRS).

«free-viewing task»

80

WFESEPB.

( H- ) .

H-

98

: 34

, 34

, 31

(3746,5  
 [2960,25–4441,75] ) (4529 [3827,5–4915] ), p=0,039.  
 (4305 [3217–5074] )  
 [5128 [4587–5740] ), p=0,005.  
 (4558 [4103,5–5016] ), p=0,083.

(210,5 [-394,75–816] ) (945 [294–1572,5] ), p=0,039,  
 [378 (-380,5–1350) ] [1054 (531–2121) ],  
 p=0,047.

,  
 ,  
 :  
 ,  
 ,  
 ;  
 ,  
 [5].

1. Shamai-Leshem D., Linetzky M., Bar-Haim Y. Attention Biases in Previously Depressed Individuals: A Meta-Analysis and Implications for Depression Recurrence // *Cogn. Ther. Res.* 2022. Vol. 46. P. 1033–1048.

2. Sun R., Fietz J., Erhart M. et al. Free-viewing gaze patterns reveal a mood-congruency bias in MDD during an affective fMRI/eye-tracking task // *Eur. Arc. Psychiatry Clin. Neurosci.* 2024. Vol. 274, No. 3. P. 559–571.

3. Imbert L., Neige C., Moirand R. et al. Eye-tracking evidence of a relationship between attentional bias for emotional faces and depression severity in patients with treatment-resistant depression // *Sci. Rep.* 2024. Vol. 14. P. 12000.

4. . . , . . , . .

//

. 2023. . 33, 4. . 39–47.

5. Miskowiak K.W., Seeberg I., Kjaerstad H.L. et al. Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task force // *Bipolar Disord.* 2019. Vol. 21, No. 8. P. 686–719.

,  
 ,  
 . . <sup>1</sup>, . . <sup>2</sup>  
 1,2  
 « 1 »,

2

E-mail: *mr.oleychik@mail.ru*

[1].

(

( $\mu=22,4$ )

75

( )  
18 25

( , ).

.. .

» (H-h) [2] « » ( ) [3].

SPSS

Statistics.

1. Hannula, D. E., et al. (2021). "Cognitive impairments in depression: A review of neuroscience approaches." *Journal of Affective Disorders*, 295, 512-524.

2. . . . . : . . . . . 2.

. . . . . 2018;(4):26-34. <https://doi.org/10.31363/2313-7053-2018-4-26-34>

3. . . . . // . . . . . , 2006. 4 :

*E-mail: jackfrost14.12@gmail.com*

( - )

( )

rs1130864 CRP,

[1,2].

rs1130864

CRP

16-25 ( . . . . . - 21±2,29 ). 80  
(F20, F21, F23, F25 -10),  
44

[3].

(RAVLT), 72 , 28 ( ) [4].  
44

Rewards Task (EEfRT), Effort Expenditure for  
( ) [5].

JASP.

rs1130864 (rho=0.31, p=0.05). ANOVA, (F=1.57, p=0.214); F=0.04, p=0.844, F=0.71, p=0.401). (F=5.13, p=0.025) (F=4.38, p=0.038), (F=2.01, p=0.159)

CRP G rs1130864

rs1130864

1. Morita A. et al. Polymorphism of the C-reactive protein (CRP) gene is related to serum CRP Level and arterial pulse wave velocity in healthy elderly Japanese //Hypertension research. – 2006. – . 29. – . 5. – . 323-331.

2. Schulz S. et al. C-reactive protein level and the genetic variant rs1130864 in the CRP gene as prognostic factors for 10-year cardiovascular outcome //Cells. – 2023. – . 12. – . 13. – . 1775.

3. Fusar-Poli P. et al. The psychosis high-risk state: a comprehensive state-of-the-art review //JAMA psychiatry. – 2013. – . 70. – . 1. – . 107-120.

4. Boone K. B., Lu P., Wen J. Comparison of various RAVLT scores in the detection of noncredible memory performance //Archives of Clinical Neuropsychology. – 2005. – . 20. – . 3. – . 301-319.

5. « (EEfRT) // 2019. – . 8. – . 4. – . 138-155.

60

*valeriya.pochueva@gmail.com*

[1].

VLOSLP) 40 (late-onset schizophrenia, LOS) (very late onset schizophrenia-like psychosis, 60 [2].

[3],

[4].

(... , ... . .) ( ,  
 - . . . . . . .). 65 ,  
 60 ,  
 : F20.0 - (n=23), F22.81 -  
 (n=7), F06.2 - (n=7), F25 -  
 (n=11). C 72,5 [63,5; 78,5] ,  
 - 69 [62; 76] , 62 , 3 .

60  
 ,  
 . 3 - , 25  
 , 2 3 .

28 , 3  
 2 .

30 ,  
 3 ,  
 « » , , , .  
 . 49%

3 .  
 1 ,  
 10 .  
 -  
 « » .

1 2  
 ,  
 2 ,



1. Van Assche L, Van Aubel E, Van de Ven L, Bouckaert F, Luyten P, Vandenbulcke M. The Neuropsychological Profile and Phenomenology of Late Onset Psychosis: A Cross-sectional Study on the Differential Diagnosis of Very-Late-Onset Schizophrenia-Like Psychosis, Dementia with Lewy Bodies and Alzheimer's Type Dementia with Psychosis. *Arch Clin Neuropsychol*. 2019; 34(2): 183-199. doi: 10.1093/arclin/acy034.

2. Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. *Am J Psychiatry*. 2000 Feb;157(2):172-8. doi: 10.1176/appi.ajp.157.2.172.

3. Sharma ER, Debsikdar AV, Naphade NM, Shetty JV. Very Late-onset Schizophrenia Like Psychosis: Case Series and Future Directions. *Indian J Psychol Med*. 2014 Apr;36(2):208-10. doi: 10.4103/0253-7176.130999.

4. Belbeze J, Gallarda T. Very-late-onset psychotic symptoms: psychosis or dementia? A phenomenological approach. A systematic review. *Geriatr Psychol Neuropsychiatr Vieil*. 2020 Mar 1;18(1):77-86. doi: 10.1684/pnv.2020.0868.

. .<sup>1</sup>, . .<sup>2</sup>

1

«

. . . . . »

2 . . . . . ,

«

. . . . . »

*E-mail: purginevgeny@gmail.com, gorobetsln@mail.ru*

—

[1].

[2,3].

[4].

[5–7],

21 63 (37 43 ), 80  
 « 4 . . . » ,  
 16 9 .  
 -10. 50 (20  
 30 ) 21 65 .  
 :

PANSS (Kay S. et al., 1987),  
 BNSS (Kirpatrick B. et al., 2011),  
 PSP (Morosini P. et al., 2000; Nasrallah H. et al., 2008),  
 (Addington D. et al., 1990), « » (Baron-  
 Cohen S. et al., 2001), (Mehrabian A., 1972).

1.

		(n=80)		(n=50)	
		n	/	n	/
	*	37	189,1±94,5	20	224,7±119,2
		43	191,7±95,6	30	198,3±115,3
	18 41 *	37	184,8±92,8	35	216,1±119,6
	42 65	43	195,4±97,3	15	192,0±110,2
	*	40	190,7±94,8	44	218,9±121,7
	*	40	190,4±95,6	6	135,3±74,9
	/	44	190,3±95,2	45	202,8±113,2
	*	36	190,8±95,4	5	263,7±144,2
		35	191,1±96,3	23	199,1±112,1
		45	190,1±94,5	27	217,2±120,8
		<b>80</b>	<b>190,5±95,3</b>	<b>50</b>	<b>208,9±117,0</b>

\*p<0,05 (U- )

« »

(p<0,05).

41

190,5±95,3 / , (n=80)  
 (n=50) 208,9±117,0 / (p=0,19),

1. . . . .  
// . – 2024. – . 34, 1. – . 95-102.  
DOI 10.34757/0869-4893.2024.34.1.009.
2. . . . .  
// . . 2014. 6–1.  
. 81–87
3. Bechi M., Riccaboni R., Ali S. Theory of mind and emotion processing training for patients with schizophrenia: preliminary findings // *Psychiatry Res.* 2012. Vol. 198(3). P. 371-377. doi:10.1016/j.psychres.2012.02.004
4. . . . .  
//  
. – 2023. – . 33, 3. – . 69-80.
5. Barchi-Ferreira A.M., Osório F.L. Associations between Oxytocin and Empathy in Humans: A Systematic Literature Review // *Psychoneuroendocrinology.* 2021. Vol. 129. 105268. doi: 10.1016/j.psyneuen.2021.105268
6. Rubin L.H., Carter C.S., Drogos L., Pournajafi-Nazarloo H., Sweeney J.A., Maki P.M. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia // *Schizophr Res.* 2010. Vol. 124(1-3). P. 13-21. doi:10.1016/j.schres.2010.09.014
7. Strauss G.P., Keller W.R., Koenig J.I., Sullivan S.K., Gold J.M., Buchanan R.W. Endogenous oxytocin levels are associated with the perception of emotion in dynamic body expressions in schizophrenia // *Schizophr Res.* 2015. Vol. 162(1-3). P. 52-56. doi:10.1016/j.schres.2015.01.022

. . .  
I, . . . I

I

. . . .

*E-mail: eremeydiadin@gmail.com*

1982), ( , 1991), ( , 1982), ( , 1973) [1]. [2,3].

[4].

1. // . – 2001
2. Freud S. Das Ich und das Es. Leipzig; Vienna; Zurich: Internationaler Psychoanalytischer Verlag;(1923).
3. Reich W. Die Funktion des Orgasmus. 6th Edn. Cologne: Kiepenheuer & Witsch; (1997).
4. Rosendahl S, Sattel H, Lahmann C. Effectiveness of Body Psychotherapy. A Systematic Review and Meta-Analysis. Front Psychiatry. 2021 Sep 9
5. The Handbook of Body Psychotherapy & Somatic Psychology Edited by Halko Weiss, Gustl Marlock, & Courtenay Young. Publishing North Atlantic Books, Berkeley, California 2015.
6. //
7. . 2019. 3. //
8. Classen CC, Hughes L, Clark C, Hill Mohammed B, Woods P, Beckett B. A Pilot RCT of A Body-Oriented Group Therapy For Complex Trauma Survivors: An Adaptation of Sensorimotor Psychotherapy. J Trauma Dissociation. 2021 Jan-Feb;22(1):52-68.

9. Guilbaud O., Corcos M., Hjalmarsson L., Loas G., Jeammet P. Is there a psychoneuroimmunological pathway between alexithymia and immunity? Immune and psychological correlates of alexithymia // Biomed. Pharmacother. – 2003. – Vol. 57, N 7. – P. 292-295.

10. . . . (2010)

//

. 6. . 62–67.

11. . . .

. 2022. 74-2.

« »

*E-mail: samarina95@mail.ru*

[1; 2].

[3].

– 753, 2022 – 679 (-9,8 % 2021 ) [4]. : 2020 – 548 (-30,4% 2018 ), 2021

[5]:

( ), ( ),  
( , , , ) [6,7].

( 14-18 , - F21.x, F84.5, F9x, )  
( , )  
, 22 (5 , 17 ).

: 3,4: 1.  
16,1 ± 1,2 .  
. 18 (14 , 4 )

3-

. 15 (68,2%)  
,  
. 7 (31,8%)



- [1].
- [2].
- [3].
- [4].
- «CoCoPop» (PubMed, (eLibrary), Google Scholar. 2000 18 «JBI» [4].
- $I^2$  Q.

1. Ayano G. et al. The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses // *J. Affect. Disord.* 2023. Vol. 339. P. 860–866.

2. ( ) / . . . , . . . , . . . // . . . - 2013. - . 20, - 3. - . 91–97.

3. Cortese S. et al. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study // *Mol. Psychiatry.* 2023. Vol. 28, 11. P. 4823–4830.

4. Munn Z. et al. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data // Int. J. Evid. Based Healthc. 2015. Vol. 13, 3. P. 147–153.

-

:

. . .<sup>1</sup>, . . .<sup>2</sup>, . . .<sup>3</sup>, . . .<sup>4</sup>

1 . . .<sup>2</sup> . . .  
3 . . .  
4 . . .  
« »

E-mail: sizov.stepan@list.ru

-

( ),

[1, 2, 3].

70  
18 55 ( – 36,2±10,2 )

(F31.1-2) – 16 (22,9%),  
(F25.0) – 18 (25,7%).

(51,4%) 55

30 (42,9%)

(« » ) (17 , 24,3%)  
, 18,6%). (« » ) (13  
40 (57,1%),

(« » ) (22 / , 31,4%)

») (18 , 25,7%). ( «

(p>0,05).

1- (p<0,05),  
« » (p>0,05).



« »  
 « »  
 ( )  
 « »  
 (237,6 (205,5-271,0) / , p<0,05) 1- (47,3 (40,9-53,2) / ,  
 p<0,05), S100b (0,9 (0,82-0,95) . . . , p<0,05)  
 « »  
 (250,6  
 (224,0-261,0) / , p<0,05). (p>0,05).  
 YMRS ( =0,52, p=0,01)  
 – « »  
 .  
 -  
 ,  
 .  
 -  
 « » « »  
 ,  
 .

1. Perugi G. Chronic mania: Family history, prior course, clinical picture and social consequences / Perugi G., Akiskal H.S., Rossi L., Piano A., Quilici C., Madaro D., et al. // Br J Psychiatry. – 1998. – Vol. 173. – P. 514-518.

2. Malhi GS. Rediscovering chronic mania / Malhi GS, Mitchell PB, Parker GB. // Acta Psychiatr Scand. – 2001. – Vol. 104. – N. 2. - 153-6. Doi: 10.1034/j.1600-0447.2001.00289.x.

3. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology / Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, Coghill DR, Fazel S, Geddes JR, Grunze H, Holmes EA, Howes O, Hudson S, Hunt N, Jones I, Macmillan IC, McAllister-Williams H, Miklowitz DR, Morriss R, Munafò M, Paton C, Saharkian BJ, Saunders K, Sinclair J, Taylor D, Vieta E, Young AH. // J Psychopharmacol. – 2016. – Vol. 6. – P. 495-553. Doi: 10.1177/0269881116636545.

:

. . .<sup>1</sup>, . . .<sup>2</sup>

1

2

( ), ,  
 «  
 » , ,



43,3%), (9,30%). (13,61,5%), (8,13,5), (5,13,38,5%).

H1- (D2- 1- (5-HT2A 5-HT2C- D2- [8].

(, ), (, ), (, ).

1. Burks W., Helm R., Stanley S. et al. Food Allergens // *Curr. Opin. Allergy Clin. Immunol.* — 2001. — Vol. 1. — P. 243–248.

2. . . . . 2015. 7.

3. Gupta M.A. Somatization Disorders in Dermatology. *Int. Rev. Psychiatry.* 2006;18:41–47

4. . . . . 4-5, 15, 2017.

5. Broom B.C. A reappraisal of the role of ‘mindbody’ factors in chronic urticaria // *Postgrad Med J.* 2010. Vol. 86. P. 365–370.

6. . . . . 2014;(3):21–26.

7. Edin A.S. To the question of the use of alimamazine (Teraligen®) in patients with atopic dermatitis in combination with anxiety-depressive disorder. Consil. Med. 2018; 20 (2): 145–150.;

8. . . . . (

« »): . 2024; 20 (28): 6–14. DOI 10.33978/2307-3586-2024-20-28-6-14

. . .<sup>1</sup> . . .<sup>1,2</sup>

« . . . - »<sup>1</sup> 3

« - . . . »<sup>2</sup>

*stomovat@rambler.ru*

[1, 2].

[3].

[4,5].

[6].

2006-2023 .;

2016 – 2023

2023 .

2023

95%

( (95% )).

1028

79 [70,0; 87,0]

2016 2023

52.5% -

2016 2023 .

- 29 [12,0; 70,0]

128,5

2020

- 214 .,

COVID - 19.

(p=0,161).



..

..

( )

E-mail: doc.tveritina@gmail.com

: ( ) /

Serbskiy V.P., 1912], [Morozov P.V., 1977; Medvedev V.E., 2016], [Kraepelin E., 1915; DSM-5, ICD-11], [Dallempagne J., 1894; Korkina M.V., 1984; Phillips KA, 2006; Loréa N, Van Wijnendaele R, 2011].

/ - ( )

[Matyushenko E.N., 2013].

- 31,5±7,3 ), 17 ( ' 16 ,

(« » / c , n=13),  
(« » , n=4).

( ( , .). ( , .),



2023 , - 18,9 % . 28,9 %

« » ,

2022 . 11,8 % ,

« » . 2023 1,83% .

- 24,6% 2022 .

2022 " - " -

- . 2023

» .

6 ,

» .

« » .

3 6 .



(<https://nayamale.ru/shop>),

« »

2023

9% ( 2022 – 24,6%)

( , )

. . .<sup>1,2</sup>, . . .<sup>1</sup>, . . .<sup>1,2</sup>

1

2

*E-mail: olga.filileeva@gmail.com*

( ).

[1],

[2-5].

[6, 7].

: c

(n=10). (n=18), (n=12), 40  
 ( - 54,15±12,7, . - 22,5%, . - 72,5%),  
 (GAD-7), (PHQ-9), (SOMS-2)  
 (SCID-II) ( ) .  
 : 70% 11% 33%  
 (61,1%, 25%, 40%), (16,67%, 16,67%, 20%),  
 (5,56%, 33,33%, 60%) (66, 7%, 33,3%, 40%),  
 (GAD-7), (PHQ-9) (SOMS-2)  
 ( - 8,9±6,8 ( ), 6,8±5,6 ( ), 8,3±4,5 ( ),  
 -0,635), ( - 9,4±6,3 ( ),  
 7,83±6,1 ( ), 13,3±8,6, p=0,283 ),  
 ( ) 29,4±12,0 ( ), - 27,5±11,5 ( ) 29,3±10,9  
 ( ) -0,808).

(F2).

(F20 F22 - ) - 41,7% 0%  
 20% (F21) - 25% 20%  
 SCID-II  
 - 4,% ( 1,8%  
 4,0% ), - 2,8% ( -  
 2,8% - 3% ( 1% 1,6% 0% ), -  
 (25%) 15% (40%)

1. Tabeeva GR. Neck pain: a clinical analysis of causes and therapy priorities. *RJTAO*. 2019;11(2S):69-75. doi:10.14412/2074-2711-2019-2S-69-75
2. Xu Y, Wang Y, Chen J, et al. The comorbidity of mental and physical disorders with self-reported chronic back or neck pain: Results from the China Mental Health Survey. *Journal of Affective Disorders*. 2020;260:334-341. doi:10.1016/j.jad.2019.08.089
3. Webb R, Brammah T, Lunt M, Urwin M, Allison T, Symmons D. Prevalence and Predictors of Intense, Chronic, and Disabling Neck and Back Pain in the UK General Population: *Spine*. 2003;28(11):1195-1202. doi:10.1097/01.BRS.0000067430.49169.01
4. Von Korff M, Crane P, Lane M, et al. Chronic spinal pain and physical–mental comorbidity in the United States: results from the national comorbidity survey replication. *Pain*. 2005;113(3):331-339. doi:10.1016/j.pain.2004.11.010
5. Ahrens C, Schiltenswolf M, Wang H. Gesundheitsbezogene Lebensqualität (SF-36) bei chronischen Rückenschmerzen und gleichzeitiger Depression. *Schmerz*. 2010;24(3):251-256. doi:10.1007/s00482-010-0923-1
6. . . . . . , 2023
7. Mun CJ, Ruehlman L, Karoly P. Examining the Adjustment Patterns of Adults With Multiple Chronic Pain Conditions and Multiple Pain Sites: More Pain, No Gain. *The Journal of Pain*. 2020;21(1-2):108-120. doi:10.1016/j.jpain.2019.06.002

. . . . .<sup>1</sup>, . . . . .<sup>2</sup>  
 . . . . .<sup>1</sup> , . . . . .<sup>2</sup> . . . . .  
 « . . . . . »

E-mail: leyloka.5545@mail.ru

( ) : 50% .

[1, 2]. ,

[2, 3,





(2 - 3 - 8)  
 (HADS).

(r = 0,465  
 0,495) - (r = 0.646 0.660).  
 (r=0,544 0,557)

(r=0.538, p=0.021). Ia  
 (p 0.001).  
 2.5  
 Ia -  
 (3 2 ) c

HADS

	1.5	1.5	2.0	1.0	2.0
( )	0	0	2	0	0
( )	1	3	3	1	0
( )	3	3	3	2	3
( )	1	2	2	1	3
( )	1	1	1	1	2
HADS	11	14	16	10	14
HADS	15	17	17	9	10
/					

1. Martin S, Vincent A, Taylor AW, et al. Lower Urinary Tract Symptoms, Depression, Anxiety and Systemic Inflammatory Factors in Men: A Population-Based Cohort Study. PLoS ONE. 2015;10(10):e0137903. doi:10.1371/journal.pone.0137903;
2. Breyer BN, Shindel AW, Erickson BA, Blaschko SD, Steers WD, Rosen RC. The association of depression, anxiety and nocturia: a systematic review. J Urol. 2013;190(3):953-957. doi:10.1016/j.juro.2013.03.126
3. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-2223. doi:10.1016/s0140-6736(12)61689-4

*E-mail: nikita.cherkasov@hotmail.com*

[1].

( ) [2].

[3].

– 71 ..

– 15),

82

(71 ..


(MMSE, MoCA, FCSRT)

(NPI-Q, MBI-C).  
 $p < 0.001$ .


( ),  
 ; (2)  
 ( )

: (1)

1



. 1



. 2

( .1). 2

( .2)

( $r = 0.25$ )

( $r = 0.28$ ),

FCSRT ( $r$

= -0.24).

( $F$ ,  $R^2$ , Adjusted  $R^2$ , Residual Std. Error)

( .1).

1.

Dependent variable:

( )

	(1)	(2)
( )	0.13	0.10
MMSE		0.11
FCSRT ( )		-0.13
( )		0.03
( )	0.22	0.03
	0.08	0.44
	0.08*	0.09
Constant	-4.92	0.08
		-6.06



Observations	82	82
R <sup>2</sup>	0.06	0.12
Adjusted R <sup>2</sup>	0.01	0.03
Residual Std. Error	3.02 (df = 77)	3.00 (df = 73)
F Statistic	1.22 (df = 4; 77)	1.29 (df = 8; 73)
Note:	*p<0.1; **p<0.05; ***p<0.01	

1. : 2 . / . . . 1. — : , 1999. — 479. — 74 .; ISBN 5-225-04394-1.

2. Bock MA, Bahorik A, Brenowitz WD, Yaffe K. Apathy and risk of probable incident dementia among community-dwelling older adults. – *Neurology*. – 2020. – 95. – 3280–3287. <https://doi.org/10.1212/WNL.00000000000010951>

3. Ma L. Depression, Anxiety, and Apathy in Mild Cognitive Impairment: Current Perspectives. *Front Aging Neurosci*. – 2020. – 12. – 9. doi: 10.3389/fnagi.2020.00009.

« »

*E-mail: railya2591@yandex.ru*

[1].

[2].

[3],

[4],

[5].

200

– 3,22±8,44

– 2,56; 5 7 3,27 7 3,56.

– 1,73;

39,8±10,3

(The Self-Stigma Of

Mental Illness Scale (SSMIS)) [6].

SSMIS « »

1. Falconer R, Tang J. How well do policymakers address stigma surrounding substance use disorders: lessons from a qualitative review of Scottish Alcohol and Drug Partnerships' strategic plans. *Front Public Health*. 2023 Jun 30;11:1209958. doi: 10.3389/fpubh.2023.1209958. PMID: 37457267; PMCID: PMC10348887.

2. Zayts-Spence O, Edmonds D, Fortune Z. Mental Health, Discourse and Stigma. *BMC Psychol*. 2023 Jun 12;11(1):180. doi: 10.1186/s40359-023-01210-6. PMID: 37308939; PMCID: PMC10259033.

3. Finn SW, Mejlidal A, Nielsen AS. Public stigma and treatment preferences for alcohol use disorders. *BMC Health Serv Res*. 2023 Jan 24;23(1):76. doi: 10.1186/s12913-023-09037-y. PMID: 36694198; PMCID: PMC9872434.

4. Griffin SM, Karia FP, Zimmerman A, Minnig MCC, Swahn M, Makelarski J, T Mmbaga B, Vissoci JRN, A Staton C. A Mixed-Methods Study: Sex Differences in Experiences of Stigma Associated With Alcoholism and Alcohol Use Disorders Among Injury Patients in Tanzania. *Alcohol Clin Exp Res*. 2020 Aug;44(8):1700-1707. doi: 10.1111/acer.14402. Epub 2020 Aug 9. PMID: 32583874; PMCID: PMC7480464.

5. Moore KE, Stein MD, Kurth ME, Stevens L, Hailemariam M, Schonbrun YC, Johnson JE. Risk Factors for Self-stigma among Incarcerated Women with Alcohol Use Disorder. *Stigma Health*. 2020 May;5(2):158-167. doi: 10.1037/sah0000182. Epub 2019 Jul 25. PMID: 33102697; PMCID: PMC7583578.

6. Schomerus G, Corrigan PW, Klauer T, Kuwert P, Freyberger HJ, Lucht M. Self-stigma in alcohol dependence: consequences for drinking-refusal self-efficacy. *Drug Alcohol Depend*. 2011 Mar 1;114(1):12-7. doi: 10.1016/j.drugalcdep.2010.08.013. Epub 2010 Oct 8. PMID: 20933344.

1, 2

1  
2  
« »

E-mail: ttnszy@gmail.com

[1].

25

(  
» (F20), 10 - « (23 ± 2,6 ).  
» (F25.0-2).

(COGDIS)

COPER [2],

COGDIS 13,3 ± 13,6  
COPER 9,3 ± 10,7. COGDIS 8,5 ± 8,33.

[2].

10 (40%), 15 (60%) -

(COGDIS) 6 (24%), - 76%.  
- 42,4±10,8 , 8,1±3,2, (p=0,002).

(r=0,32).

[1],

« ».

[2],

- 1. // . – 2011. – . 27–28 – 1–2 – . 63–69. / . . .
- 2. // . – 2024. – . 124 – 6 – . 94–100.

*E-mail:yudelevich.d@gmail.com*

[1]

[2]

[3].

16 ,

( 32.6, 102 ),  
2023

« » , 4 1,5

( 27% ). 2023 75

46.7 , 14.6 .



[2].

[7].

[3].

[5].

[4].

[4].

[8].

[8].

[1].

[7, 9].

[6].

[4].

1. Bangasser D. A. [ ]. Sex differences in stress regulation of arousal and cognition // *Physiology & Behavior*. 2018. (187). C. 42–50.
2. Bromet E.J. [ ]. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. *Arch Gen Psychiatry*. 2009;66:785. 2009. (66). C. 785.
3. Canuto A., Weber K., Baertschi M. Anxiety disorders in old age: psychiatric comorbidities, quality of life, and prevalence according to age, gender, and country 2018. 26. C. 174–85.
4. Christiansen D. M., Berke E. T. Gender- and Sex-Based Contributors to Sex Differences in PTSD // *Current Psychiatry Reports*. 2020. 4 (22). C. 19.
5. Christiansen D.M. Mediation and moderation effects of sex and gender in PTSD 2017.
6. Holmes A., Singewald N. Individual differences in recovery from traumatic fear // *Trends in Neurosciences*. 2013. 1 (36). C. 23–31.
7. Kimerling R., Allen M. C., Duncan L. E. Chromosomes to Social Contexts: Sex and Gender Differences in PTSD // *Current Psychiatry Reports*. 2018. 12 (20). C. 114.
8. Lee M. R. [ ]. Gender differences in neural–behavioral response to self-observation during a novel fMRI social stress task // *Neuropsychologia*. 2014. (53). C. 257–263.
9. Swaab D. F., Bao A.-M. Sex differences in stress-related disorders: Major depressive disorder, bipolar disorder, and posttraumatic stress disorder Elsevier, 2020.C. 335–358.

IV

...

21 :

:

ISBN 978-5-907826-09-0



9 785907 826090 >

« »

121359, . , . 19, . 1A  
+ 7 (499) 140-20-78

17.12.2024

60x84/16.

«Times». 100 .

« »

101000, , . , .17, . 1